Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Stomach Neoplasms 6Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Head and Neck Neoplasms 1HER2-low Breast Cancer 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Biliary Tract Neoplasms 1

Interventions

disitamab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muscle Invasive Bladder Carcinoma × disitamab vedotin × Clear all
NCT06074484 2023-10-10

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
36 enrolled

Muscle Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡